Search

everythinglearnresearchcommunity

for

Search:↓

Ginsenoside Rg3 from Panax ginseng can lighten skin by reducing melanin production.

BMP signaling prevents hair growth by stopping stem cell activation.

The RNA AL136131.3 slows down hair growth and speeds up hair loss by affecting sugar breakdown in hair follicles.

Specific miRNA profiles can help diagnose and treat alopecia areata.

Unique microRNA patterns can help diagnose and treat severe alopecia areata.

Certain medications, including some immune drugs, contraceptives, and hair loss treatments, are often linked to hair loss.

Blocking certain pathways with kinase inhibitors may help treat cutaneous lupus erythematosus.

A 50 mg non-loading dose of ritlecitinib is safe for adults and adolescents.

The model successfully predicted new uses for existing drugs, like using certain hormonal and heart medications for respiratory and Parkinson's diseases, and a cancer drug for diabetes.

A man developed a rash similar to pityriasis rubra pilaris after starting sorafenib for cancer, possibly due to the drug's effect on skin cells.

Ritlecitinib can help about 14,000 people with severe hair loss.

The JAK/STAT pathway is important in cell processes and disease, and JAK inhibitors are promising for treating related conditions.

Some treatments can help with a hair loss condition called alopecia areata, but none ensure lasting results; choices depend on the person, with JAK inhibitors showing promise for severe cases.

A man with vitiligo and alopecia saw quick skin and hair improvement with ruxolitinib, but skin color gains were lost after stopping treatment.

Human dermal fibroblasts are the main cells targeted by a virus that can cause a deadly skin cancer, and a certain inhibitor can effectively block this infection.

Topical Ruxolitinib may safely treat severe hair loss.

Targeted cancer therapies often cause skin reactions, so dermatologists must manage these effects.

Animal models have helped understand hair loss from alopecia areata and find new treatments.

New treatments for Alopecia Areata, like JAK inhibitors, show promise for hair regrowth and are likely to change future treatment approaches.

A patient with alopecia areata regrew hair after taking tofacitinib and showed changes in certain blood and skin markers.

Netherton syndrome has two subtypes with shared immune traits but different allergic and immune responses, suggesting targeted treatments.

Alopecia areata is linked to immune-related genes, suggesting JAK inhibitors as a potential treatment.

Topical corticosteroids are the best initial treatment for children's alopecia areata.

The study concluded that immune cells attacking hair follicles cause hair loss in alopecia, with genetics and environment also playing a role, and highlighted the potential of certain treatments.

Tofacitinib helped some young children with severe hair loss grow their hair back without bad side effects.

Tofacitinib temporarily regrew hair in a man with alopecia, but its effects didn't last.

Hair loss requires customized treatments based on its various causes and types.

New treatments targeting immune pathways show promise for severe hair loss but need more research for safety and effectiveness.

Tofacitinib shows promise for treating severe hair loss in adults and teens, with many experiencing regrowth, but hair loss returns when treatment stops.

SOCS1 and SOCS3 help control skin inflammation and are important for developing treatments for skin diseases.